Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer

NCT06279351 is registered in ClinicalTrials.gov with Xinqiao Hospital of Chongqing as lead sponsor.

NCT NCT06279351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06279351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Lead sponsor
Xinqiao Hospital of Chongqing
Phase
Phase 2
Overall status
Recruiting
Start date
August 11, 2024
Completion date
December 31, 2025
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thalidomide enhances clinical efficacy of cetuximab combined with standard chemotherapy for left colorectal cancer